Adverse Drug Reactions, Advice and Consulting ADR-AC   Report issue

For profit Phase 3
Founded: Bern Switzerland (2006)

Organization Overview

First Clinical Trial
2012
NCT01803763
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

omalizumab (xolair) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Urticaria (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1